Lumida
/TSHA
⌘K
Taysha Gene Therapies Inc

Taysha Gene Therapies Inc

TSHA
$5.02USD↓-2.71%-0.14 today

MARKET CAP

1.6B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$7

AI Summary

Stalk
TrimMedium

TSHA remains in medium-term distribution with active lower highs and lower lows under declining EMAs, trading near extreme oversold levels at the 200-day SMA. The medium-term bias is bearish, but short-term exhaustion and oversold RSI suggest caution on new shorts. Execution is best deferred into rallies toward the 9/20 EMA zone for rejection. The long-term uptrend stays intact above the rising 200-day SMA. Key risks include a relief bounce reclaiming the 20 EMA or a breakdown below the 200-day SMA invalidating core structural signals.

  • ↑Breakthrough therapy designation and 100% early trial response rate accelerate BLA path.
  • ↑Catalent manufacturing agreement ensures scalable supply for anticipated 2027 launch.
  • ↓Net loss of $109M and $86.4M R&D spend in 2025 strain finances.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company dedicated to advancing gene therapies for rare neurodevelopmental disorders, particularly Rett syndrome. Positioned as a pioneer in the gene therapy space, Taysha focuses on its lead candidate, TASHA-102, which aims to address the genetic root cause of Rett syndrome, a debilitating condition affecting thousands of patients globally. The company's commitment to innovation and patient welfare blends well with the growing emphasis on rare disease treatments, making it a focal point in the biotechnology landscape.

Bull says

  • ↑Breakthrough therapy designation and 100% early trial response rate accelerate BLA path.
  • ↑Catalent manufacturing agreement ensures scalable supply for anticipated 2027 launch.
  • ↑$319.8M cash provides funding through 2028, reducing financing risks.
  • ↑Estimated 15k–20k U.S. patients create sizable addressable market.
  • ↑Strong momentum and ample liquidity reflect growing investor interest.
  • ↑High institutional ownership suggests analyst confidence in upside potential.

Bear says

  • ↓Net loss of $109M and $86.4M R&D spend in 2025 strain finances.
  • ↓No near-term path to profitability amid high operating expenses.
  • ↓Intensifying competition in Rett syndrome therapies threatens market share.
  • ↓Trial enrollment delays could postpone BLA submission beyond 2027.
  • ↓Manufacturing consistency risks with Catalent integration may impact supply.
  • ↓Valuation appears stretched given weak profitability and elevated volatility.

Investment themes with TSHA

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-11-2026neutral

Transcript signals

Read full transcript analysis ›